ÁNGEL
PÉREZ NÚÑEZ
Profesor asociado de Ciencias de la Salud
AURELIO
HERNÁNDEZ LAÍN
Profesor asociado de Ciencias de la Salud
Publicaciones en las que colabora con AURELIO HERNÁNDEZ LAÍN (16)
2024
-
Low rCBV values in glioblastoma tumor progression under chemoradiotherapy
Neuroradiology, Vol. 66, Núm. 3, pp. 317-323
2022
-
A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis
EMBO molecular medicine, Vol. 14, Núm. 3, pp. e14552
-
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Nature medicine, Vol. 28, Núm. 4, pp. 752-765
2021
-
Snorting the brain away: Cerebral damage as an extension of cocaine-induced midline destructive lesions
Journal of Neuropathology and Experimental Neurology, Vol. 79, Núm. 12, pp. 1365-1369
-
Tumor-derived pericytes driven by egfr mutations govern the vascular and immune microenvironment of gliomas
Cancer Research, Vol. 81, Núm. 8, pp. 2142-2156
2020
-
Immune profiling of gliomas reveals a connection with IDH1/2 mutations, tau function and the vascular phenotype
Cancers, Vol. 12, Núm. 11, pp. 1-18
-
The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas
Science Translational Medicine, Vol. 12, Núm. 527
2019
-
Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab
Clinical and Translational Oncology, Vol. 21, Núm. 10, pp. 1413-1423
-
Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma
Oxidative medicine and cellular longevity, Vol. 2019, pp. 9719730
-
Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival
Neurocirugia, Vol. 30, Núm. 1, pp. 11-18
2018
-
Tumor cell vanishing with radiological changes suggesting progression in IDH-mutated diffuse astrocytoma treated only with surgery
Clinical Neuropathology, Vol. 37, Núm. 5, pp. 217-220
2017
-
Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab
Clinical and Translational Oncology, Vol. 19, Núm. 1, pp. 51-57
2016
2015
-
Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma
Molecular Cancer Therapeutics, Vol. 14, Núm. 7, pp. 1548-1558
2014
-
A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomas
American Journal of Neuroradiology, Vol. 35, Núm. 6, pp. 1096-1102
2012
-
The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas
American Journal of Neuroradiology, Vol. 33, Núm. 4, pp. 701-707